Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors from the central nervous technique, conolidine modulates alternate molecular targets. A Science Advancements study discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. B... https://richardv752cvr9.blogaritma.com/profile